{"links":{"feed":"https://www.erudio.com/reports/bdtx-1535-101-nct05256290/feed.json","html":"https://www.erudio.com/reports/bdtx-1535-101-nct05256290","json":"https://www.erudio.com/reports/bdtx-1535-101-nct05256290.json","markdown":"https://www.erudio.com/reports/bdtx-1535-101-nct05256290.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"bdtx-1535-101-nct05256290"}},"request":"https://www.erudio.com/contact?report=bdtx-1535-101-nct05256290"},"offer":{"cited_clinicians":6,"cited_commentary_sources":12,"verified_hcp_statements":37,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":6},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"bdtx-1535-101-nct05256290"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=bdtx-1535-101-nct05256290","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/bdtx-1535-101-nct05256290","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 37 verified statements · 19 from 6 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T08:01:05.828505Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":16,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":8,"title":"Primary endpoint: Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":1,"title":"Primary endpoint: Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose"},{"claim_count":4,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":2,"title":"Secondary endpoint: Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM)"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":7,"title":"Secondary endpoint: Phase 2: To assess progression free survival by RECIST version 1.1"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)"},{"claim_count":13,"coverage":"discussed","id":"T7","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T9","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T10","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":8,"coverage":"discussed","id":"A1","source_count":6,"title":"CNS activity as a clinically important but narrowly supported signal"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":3,"title":"GBM rationale and disease-specific uncertainty"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":3,"title":"Mechanistic expectations versus demonstrated clinical differentiation"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":1,"title":"Biomarker work-up and resistance-informed selection"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":2,"title":"Competitive positioning, registration uncertainty and alternative treatment strategies"},{"claim_count":1,"coverage":"discussed","id":"A6","source_count":1,"title":"Oral convenience and conditional quality-of-life value"},{"claim_count":8,"coverage":"discussed","id":"A7","source_count":7,"title":"Evidence maturity and the questions speakers left open"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":3,"cited_clinicians":6,"cited_clinicians_by_role":{"physician":2,"physician, Medical oncology":4},"cited_physicians":6,"cited_sources":12,"claims_by_expression_type":{"comparison":4,"experience":3,"interpretation":10,"opinion":8,"question":1,"restatement":6,"uncertainty":5},"claims_by_kind":{"source_observation":37},"clinician_statements":19,"evidence_units":26,"findings":7,"organisational_accounts":2,"people_cited":9,"people_identity_verified":6,"people_total":9,"screened_sources":25,"verified_claims":37},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":4},"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"After dose cuts: what speakers say","evidence_line":"6 statements from 2 speakers in 3 sources, 1 of them a podcast or video"},{"cited_clinicians":3,"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":5},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":4,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Silevertinib's future: where speakers split on non-classical EGFR NSCLC prospects","title_holders":{"cited_claim_ids":["claim-8722b4a67f0d67808a39","claim-df972bde77e38b2577a8","claim-6c1c1686ab3683b7fb09","claim-d39bc80669b8b0cca478","claim-ac8114729ba359802893","claim-4a6349a12eca831d03ac","claim-7856b0c8f889aa7910c9"],"clinicians":false,"holders":4,"speakers":4,"view":"split"},"evidence_line":"7 statements from 4 speakers in 6 sources","holder_line":"4 of the 4 named speakers in this finding take a side on this question"},{"cited_clinicians":5,"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":1,"questions":1,"restated":0,"views":6},"limitations":4,"links":{"context":1,"support":12},"ma_question":true,"named_voices":6,"passages":9,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"Non-classical EGFR: what speakers say","evidence_line":"10 statements from 6 speakers in 9 sources, 1 of them a podcast or video"},{"cited_clinicians":4,"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":7},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Silevertinib: most speakers note a CNS signal, but one has wider doubts","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-7856b0c8f889aa7910c9"],"clause":"one has wider doubts","holders":1},"cited_claim_ids":["claim-8722b4a67f0d67808a39","claim-df972bde77e38b2577a8","claim-7d0a78855380052cb209","claim-7856b0c8f889aa7910c9","claim-a04b94fce5393ab2f877","claim-3987f3447bd196245a54"],"clinicians":false,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"9 statements from 5 speakers in 6 sources, 2 of them podcasts or videos","holder_line":"4 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one has wider doubts”"},{"cited_clinicians":1,"id":"F5","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":2,"questions":4,"restated":5,"views":5},"limitations":4,"links":{"context":0,"support":18},"ma_question":true,"named_voices":4,"passages":12,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Mutation targeting, CNS penetration: some speakers see potential but seek validation","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-f8831df8efea36bfab61","claim-cd71239ced66fdf31860","claim-738be7497f19bcbc2424","claim-546130b98164cbe434d4","claim-f0dfd8d8d496278a47cb"],"clause":"seek validation","holders":3},"cited_claim_ids":["claim-57aa0c0d5c60831b2fe1","claim-db600951ec6cc641f01f","claim-24240af8797c51bc801c","claim-f8831df8efea36bfab61","claim-cd71239ced66fdf31860","claim-c3861194deac304427ae","claim-80b989deb0cfce70d338"],"clinicians":false,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"17 statements from 4 speakers in 5 sources, 3 of them podcasts or videos","holder_line":"2 of the 4 named speakers in this finding hold this view; 3 of the 4 hold its caveat, “seek validation”"},{"cited_clinicians":1,"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Oral use: a clinician values convenience but ties QoL gains to efficacy & tolerability","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-90390e3d30cc713fde38"],"clause":"tie QoL gains to efficacy & tolerability","holders":1},"cited_claim_ids":["claim-90390e3d30cc713fde38"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 3 sources, 2 of them podcasts or videos","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “tie QoL gains to efficacy & tolerability”"},{"cited_clinicians":1,"id":"F7","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Post-osimertinib: a clinician favors retesting and asks how to tailor care","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b66894ba6dd2c8dd42e4"],"clause":"ask how to tailor care","holders":1},"cited_claim_ids":["claim-8f73c0b4f0d3201d533a"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “ask how to tailor care”"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account questions pivotal-dose confidence; a video account emphasizes benefit after reductions"},{"id":"section-2","level":2,"title":"One X account sees registration uncertainty and a competitor as reasons for less enthusiasm"},{"id":"section-3","level":2,"title":"Several X accounts welcome non-classical EGFR activity; one awards a “SILVER” rather than “gold” medal"},{"id":"section-4","level":2,"title":"A video account prioritizes CNS activity; one skeptical X account still acknowledges a CNS signal"},{"id":"section-5","level":2,"title":"Interviewees frame mutation coverage and brain penetration as promises requiring further validation"},{"id":"section-6","level":2,"title":"One investigator values oral convenience but makes quality-of-life benefit conditional on tolerability"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"One interview emphasizes molecular reassessment and asks how to individualize post-osimertinib choices"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T2","label":"Primary endpoint: Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T3","label":"Primary endpoint: Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose"},{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":4}],"id":"T4","label":"Secondary endpoint: Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"Secondary endpoint: Phase 2: To assess progression free survival by RECIST version 1.1"},{"findings":[],"id":"T6","label":"Secondary endpoint: Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":2}],"id":"T7","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T8","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":5}],"id":"T9","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T10","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T08:01:05.828505Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T08:14:29Z","record_hash":"f2809b6df965b7d842b55312582f974b53c3c6a5ff506ee700bb952c4fbd4565","release_hash":"bc5e323ecc8c667372798668ea1e8f5536d8256581c3000b9e04f8cb9beca9b7","report_id":"erudio-nct05256290","run_id":"e724ff3b-1b0d-41f8-a31f-c94ce42df6ff","schema_version":"5.0","slug":"bdtx-1535-101-nct05256290","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For BDTX-1535-101, a speaker whose clinical role is unstated questions the proposed starting dose because toxicity required extensive reductions; a medical oncologist relays preserved or deeper responses in most responders following adjustment. The former also questions differentiation from firmonertinib, despite acknowledging a CNS signal. Small numbers and short follow-up qualify the favorable assessment, while cross-study comparisons leave relative benefit uncertain.","examples":[],"meta_description":"25 sources screened · 37 verified statements (19 from clinicians verified by NPI or staff page) from 12 sources · 7 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T08:14:29Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":25},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about how the inhibitor’s design enables selective targeting of oncogenic EGFR mutations; a question about initial research findings for the investigational EGFR inhibitor.","16 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 22 sources about other trials or topics are not included.","The sources reviewed for this edition do not represent all HCP discussion or support estimates of agreement, adoption or sentiment prevalence. Repeated posts and reposts should not be counted as additional independent opinions.","Discussion that does not name the trial or known aliases, or that uses different transcription variants, may be absent.","Questions introducing initial research findings and inhibitor design are not represented by available statements; some framing of the interview is therefore missing.","No exact-trial results publication, full protocol or silevertinib-monotherapy prescribing label was identified in the available material. Reported outcome and development details therefore remain attributed to the interviews, video and X accounts.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The 77% and 84% dose-reduction accounts cannot be reconciled from the statements available. Post-reduction activity does not establish the performance of a prospectively assigned 150 mg starting dose.","The video renders a mutation subset as TAF, whereas other accounts discuss PACC. The report does not correct or equate those terms.","Cross-treatment efficacy and safety appraisals are historical or cross-study interpretations, not randomized comparisons. Short follow-up and small molecular and CNS subgroups limit generalization.","Development aims from 2022, initial experience from 2023 and later congress-related accounts retain their original timing; they should not be combined into an assumed current trial status."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-09-02","start":"2022-04-05"},"retrieval_snapshot":"2026-11-20T05:45:32.450340Z","timeline":[{"count":1,"week":"2022-W14"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2025-W26"},{"count":2,"week":"2026-W21"},{"count":5,"week":"2026-W22"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W36"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05256290:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05256290:context","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:0f77c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850716192190673270:a553ed98-6f64-4086-9380-b677ad65d35f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938381872616108228:9a0e706b-32b8-4578-899c-026003fde45f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049134039085339044:c3d694ee-e1ac-4d21-aa8e-a1f0fcbe9341","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053505341820711088:fb43a751-a620-40aa-8171-1016deace841","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057638757835190768:4192c9a6-4c64-4b0c-9b15-8a36a6b5bfdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058545388702113882:06f0372e-37e0-48b4-ae72-41b4c9f2b229","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058578773549666711:5ade2415-9c10-45f6-8ebc-c00367f4a9ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059735198556910017:f6324760-3426-4118-a38b-17f5a07b771f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060805511008686195:76a3a828-ba0a-4869-9ac1-5dd27f63f090","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060805623005028809:50d59f63-daf6-4782-ae36-900fa35694d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060805830061002799:d2e68d98-b4db-4bdd-a3f3-3736a45f51d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060806352767717718:6a48edc4-d0a5-4bfd-bc4c-b832876fce28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060808068527464468:119707a4-ef70-4c74-b149-800a651f3558","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060808201558282433:44aefe40-e910-425b-93fd-e0af21f882b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060816748920676452:97259390-3a61-40ec-bb4c-556c6dc68d28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060820800177836329:7d7ed674-7511-4276-a9c5-8aa39dcb6bfe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061027841450373343:712e08f3-264d-47aa-beec-87db6f353912","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064280356044599420:b252229f-90d9-47aa-ac51-04025ae59bfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071578186295480716:edde6afb-6471-4329-90dd-a38abcfdf2c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080995740592091231:21066137-abc0-4c7e-9873-2533c9da897c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095078428437581983:1d04fa47-a543-4faa-91e0-4ec7230de5a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114392179212951939:9b52216e-4caa-47d1-affd-2547f5e29381","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4TZVMKaWL-o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:IBWAiRY4u8o","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":25},"count":25,"evidence_window":{"end":"2026-10-25","start":"2022-04-05"},"retrieval_snapshot":"2026-11-20T05:45:32.450340Z","timeline":[{"count":1,"week":"2022-W14"},{"count":1,"week":"2023-W46"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":3,"week":"2026-W21"},{"count":10,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W36"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":13,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":10}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"silevertinib","slug":"silevertinib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: Advanced Non-Small Cell Squamous Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Lung Non-Small Cell Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Advanced Lung Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Epidermal Growth Factor Receptor C797S","status":"unmapped"},{"reason":"Unmapped registry condition: Epidermal Growth Factor Receptor G719X","status":"unmapped"},{"reason":"Unmapped registry condition: EGF-R Positive Non-Small Cell Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: EGFR-TKI Resistant Mutation","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer"],"brief_title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer","Advanced Non-Small Cell Squamous Lung Cancer","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","NSCLC","Advanced Lung Carcinoma","Epidermal Growth Factor Receptor C797S","Epidermal Growth Factor Receptor G719X","EGF-R Positive Non-Small Cell Lung Cancer","EGFR-TKI Resistant Mutation"],"display_condition":"EGFR-mutated NSCLC or glioblastoma","display_interventions":[["silevertinib (BDTX-1535)"]],"enrollment":{"count":220,"type":"ESTIMATED"},"interventions":[{"name":"silevertinib monotherapy","synonyms":["BDTX-1535"],"type":"DRUG"}],"nct_id":"NCT05256290","official_title":"A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-03","type":"ESTIMATED"},"primary_endpoints":[{"description":"Dose-limiting toxicities (DLTs) in Cycle 1","measure":"Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)","timeFrame":"The first treatment 21-day cycle (Cycle 1)"},{"description":"Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1","measure":"Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)","timeFrame":"Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)"},{"description":"Treatment-emergent adverse events","measure":"Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose","timeFrame":"Through study completion, approximately 1 year"}],"registered_date":{"date":"2022-02-25","type":"ACTUAL"},"registry_last_updated":"2026-11-18","registry_url":"https://clinicaltrials.gov/study/NCT05256290","short_name":"BDTX-1535-101","short_name_basis":"sponsor_study_id","sponsor":"Black Diamond Therapeutics, Inc.","start_date":{"date":"2022-03-31","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"BDTX-1535-101","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}